✦ LIBER ✦

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

✍ Scribed by D Catovsky; S Richards; E Matutes; D Oscier; MJS Dyer; RF Bezares; AR Pettitt; T Hamblin; DW Milligan; JA Child; MS Hamilton; CE Dearden; AG Smith; AG Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen

Book ID: 117301503
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 157 KB
Volume: 370
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(07)61125-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fludarabine plus alemtuzumab versus flud

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

✍ Thomas Elter; Liana Gercheva-Kyuchukova; Halyna Pylylpenko; Tadesuz Robak; Brani 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 286 KB

Addition of rituximab to fludarabine and

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

✍ M Hallek; K Fischer; G Fingerle-Rowson; AM Fink; R Busch; J Mayer; M Hensel; G H 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 309 KB

Multicentre prospective randomised trial

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia

✍ The French Cooperative Group on CLL; S Johnson; A.G Smith; H Löffler; E Ösby; G 📂 Article 📅 1996 🏛 The Lancet 🌐 English ⚖ 1000 KB

4.19 Prediction of Poor Outcome in Chron

4.19 Prediction of Poor Outcome in Chronic Lymphocytic Leukemia Patients treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group

✍ Anna Fink; Raymonde Busch; Natali Pflug; Sebastian Boettcher; Dirk Winkler; Andr 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 115 KB

Health-Related Quality of Life in Younge

✍ Eichhorst, B. F.; Busch, R.; Obwandner, T.; Kuhn-Hallek, I.; Herschbach, P.; Hal 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 191 KB

5.40 Rituximab Maintenance in Patients w

5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC)

✍ Francesc Bosch; Pau Abrisqueta; Neus Villamor; María José Terol; Eva González-Ba 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 250 KB